TCM
CNCE

Tekla Capital Management’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History

Tekla Capital Management’s Portfolio CNCE Stock Details CNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-110,853
Closed -$1.33M – 202
2019
Q2 		$1.33M Buy
110,853
+65,491
+144% +$704K 0.05% 154
2019
Q1 		$548K Hold
45,362
– – 0.02% 178
2018
Q4 		$569K Sell
45,362
-45,362
-50% -$626K 0.02% 186
2018
Q3 		$1.35M Buy
+90,724
New +$1.43M 0.05% 175

Other funds holding CNCE

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Prudential Financial
Prudential Financial Newark, New Jersey $81.2B AUM 27.81% 1-Year Est. Return

Tekla Capital Management's CNCE Position: Q3 2019 in Review

Tekla Capital Management sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q3 2019, closing a stake of 110,853 shares — an estimated $1.33M sold.

Tekla Capital Management first reported a position in CNCE in Q3 2018 and held it in 4 quarters. The position peaked at $1.35M in Q3 2018. 80 funds tracked by Wall St. Rank hold CNCE as of Q3 2019.

  • Tekla Capital Management reported no remaining Concert Pharmaceuticals, Inc. position as of Q3 2019 after selling out during the quarter.
  • Tekla Capital Management sold 110,853 Concert Pharmaceuticals, Inc. shares in Q3 2019, an estimated $1.33M.
  • Tekla Capital Management first reported a position in Concert Pharmaceuticals, Inc. in Q3 2018 and held it in 4 quarters.
  • Tekla Capital Management's Concert Pharmaceuticals, Inc. position peaked at $1.35M in Q3 2018.
  • 80 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q3 2019.

Based on Tekla Capital Management's 13F filing for Q3 2019, filed 13 Nov 2019.